As the landscape of gynaecologic cancer treatment shifts towards treatment based on molecular classification of tumours, knowledge of targeted therapies well-suited for mismatch repair deficient Lynch tumours will be crucial.
Identifying barriers and improving access to risk reduction measures is another future direction in the study of Lynch syndrome, and perhaps the greatest frontier is determining whether Lynch-associated endometrial and ovarian tumors should be treated differently than sporadic endometrial and ovarian tumors.
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1127683/full
Lynch Syndrome Ireland 